The proposed biosensor was applied for the analysis of sera from twenty four individuals with a high risk of developing CRC and from six patients already diagnosed with ovarian and CRC, detecting low concentrations of p53 autoantibodies with an LOD of 0.34 U mL−1. This evidence concerns the gene TP53 and colorectal carcinoma.